NCT04332367View on ClinicalTrials.gov

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Carboplatin

Carboplatin IV

DRUG

Paclitaxel

Paclitaxel IV

DRUG

Ramucirumab

Ramucirumab IV

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER